MSD
@MSDInvents
We aspire to be the premier research-intensive biopharmaceutical company.
- Our Q2 2026 #earnings results are live: go.msd.com/~e4u Swipe below for perspective from Chairman and CEO Rob Davis.
- Today we announced our initial post-approval access plans for our investigational HIV prevention option. We are accelerating our access planning to help ensure that, if approved by the regulatory agency, this HIV prevention option can be accessed by those who need it in low- and
- Every day, our scientists tackle challenging problems like the scalable synthesis of complex molecules. In this latest publication in Science Magazine, we share how we’re using #biocatalysis to manufacture orally available macrocyclic peptides. Learn more: go.msd.com/~q3y
- Today, MSD completed the acquisition of Terns Pharmaceuticals, further strengthening our #oncology portfolio and reinforcing our focus on science‑driven innovation. Learn more: go.msd.com/~0bd
